This is single center, open-label phase I/II, non-randomized study which will enroll patients with recurrent advanced hepatocellular carcinoma to evaluate the safety, feasibility, and efficacy of fully human B7H3 CAR-T in treating hepatocellular carcinoma.
Subjects should be 18-70 years old.
Subject has adequate performance status as defined by ECOG score of≤ 2.
Expected life expectancy is no less than 12 weeks.
Subjects must have histologically or cytologically confirmed unresectable, recurrent and / or metastatic hepatocellular carcinoma (HCC). And tumor tissues are measured positive for B7H3 expression.
The subject is a pregnant or lactating woman.
The subjects have infectious diseases (such as HIV, syphilis, active tuberculosis, etc.);
The subject has active infection or coagulation dysfunction.
Subjects with previous hepatic encephalopathy.
The Affiliated Hospital of Xuzhou Medical University
Lead sponsor
Xuzhou Medical University
Collaborator
IIT MediTech Co. Ltd
Collaborator